OWD
ABBV icon

Osborn Williams & Donohoe’s AbbVie ABBV Stock Holding History

Osborn Williams & Donohoe’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$10.3M Buy
135,139
+1,802
+1% +$153K 1.35% 19
2019
Q4 		$11.8M Sell
133,337
-8,814
-6% -$732K 1.18% 20
2019
Q3 		$10.8M Buy
142,151
+1,243
+0.9% +$85.2K 1.08% 24
2019
Q2 		$10.2M Buy
140,908
+4,577
+3% +$360K 1.06% 25
2019
Q1 		$11.1M Buy
136,331
+11,298
+9% +$924K 1.15% 19
2018
Q4 		$11.5M Sell
125,033
-615
-0.5% -$54.1K 2.03% 9
2018
Q3 		$11.9M Sell
125,648
-313
-0.2% -$29.7K 1.85% 11
2018
Q2 		$11.7M Buy
125,961
+141
+0.1% +$13.8K 1.97% 9
2018
Q1 		$11.9M Sell
125,820
-33
-0% -$3.63K 2.06% 9
2017
Q4 		$12.2M Sell
125,853
-1,261
-1% -$119K 2.08% 8
2017
Q3 		$11.3M Sell
127,114
-3,389
-3% -$258K 2.04% 7
2017
Q2 		$9.46M Buy
130,503
+712
+0.5% +$47.9K 1.71% 12
2017
Q1 		$8.46M Sell
129,791
-804
-0.6% -$50.5K 1.53% 20
2016
Q4 		$8.18M Buy
130,595
+5,706
+5% +$348K 1.54% 18
2016
Q3 		$7.88M Sell
124,889
-4,677
-4% -$303K 1.51% 20
2016
Q2 		$8.02M Buy
129,566
+7,880
+6% +$480K 1.56% 18
2016
Q1 		$6.95M Buy
121,686
+1,822
+2% +$102K 1.39% 24
2015
Q4 		$7.1M Sell
119,864
-701
-0.6% -$40.4K 1.47% 20
2015
Q3 		$6.72M Buy
120,565
+485
+0.4% +$31.6K 1.46% 18
2015
Q2 		$8.18M Sell
120,080
-741
-0.6% -$48.4K 1.64% 13
2015
Q1 		$7.07M Buy
120,821
+4,894
+4% +$296K 1.37% 21
2014
Q4 		$7.59M Buy
115,927
+761
+0.7% +$48K 1.49% 16
2014
Q3 		$6.65M Sell
115,166
-2,088
-2% -$116K 1.39% 19
2014
Q2 		$6.44M Buy
117,254
+4,917
+4% +$258K 1.33% 20
2014
Q1 		$5.77M Buy
112,337
+4,266
+4% +$216K 1.27% 25
2013
Q4 		$5.71M Buy
108,071
+669
+0.6% +$32.9K 1.28% 22
2013
Q3 		$4.8M Buy
107,402
+5,698
+6% +$253K 1.17% 28
2013
Q2 		$4.2M Buy
+101,704
New +$4.45M 1.1% 30

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Osborn Williams & Donohoe's ABBV Position: Q1 2020 in Review

Osborn Williams & Donohoe increased its AbbVie (ABBV) stake by 1.4% in Q1 2020, buying an estimated $153K and bringing the position to 135,139 shares worth $10.3M. The position accounts for 1.35% of the portfolio, ranked #19.

Osborn Williams & Donohoe first reported a position in ABBV in Q2 2013 and has held it in 28 quarters since. The position peaked at $12.2M in Q4 2017. 2,225 funds tracked by Wall St. Rank hold ABBV as of Q1 2020.

  • Osborn Williams & Donohoe held 135,139 shares of AbbVie worth $10.3M as of Q1 2020.
  • Osborn Williams & Donohoe bought 1,802 AbbVie shares in Q1 2020, an estimated $153K.
  • AbbVie made up 1.35% of Osborn Williams & Donohoe's portfolio in Q1 2020, its #19 holding.
  • Osborn Williams & Donohoe first reported a position in AbbVie in Q2 2013 and has held it in 28 quarters since.
  • Osborn Williams & Donohoe's AbbVie position peaked at $12.2M in Q4 2017.
  • 2,225 funds tracked by Wall St. Rank held AbbVie as of Q1 2020.

Based on Osborn Williams & Donohoe's 13F filing for Q1 2020, filed 4 May 2020.